GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Prolight Diagnostics AB (LTS:0G5I) » Definitions » Debt-to-EBITDA

Prolight Diagnostics AB (LTS:0G5I) Debt-to-EBITDA : 0.00 (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Prolight Diagnostics AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Prolight Diagnostics AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr0.00 Mil. Prolight Diagnostics AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr0.00 Mil. Prolight Diagnostics AB's annualized EBITDA for the quarter that ended in Dec. 2024 was kr10.26 Mil. Prolight Diagnostics AB's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Prolight Diagnostics AB's Debt-to-EBITDA or its related term are showing as below:

LTS:0G5I's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.42
* Ranked among companies with meaningful Debt-to-EBITDA only.

Prolight Diagnostics AB Debt-to-EBITDA Historical Data

The historical data trend for Prolight Diagnostics AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prolight Diagnostics AB Debt-to-EBITDA Chart

Prolight Diagnostics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only - - N/A - -

Prolight Diagnostics AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Prolight Diagnostics AB's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Prolight Diagnostics AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prolight Diagnostics AB's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Prolight Diagnostics AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Prolight Diagnostics AB's Debt-to-EBITDA falls into.


;
;

Prolight Diagnostics AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Prolight Diagnostics AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -25.183
=0.00

Prolight Diagnostics AB's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 10.264
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Prolight Diagnostics AB  (LTS:0G5I) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Prolight Diagnostics AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Prolight Diagnostics AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Prolight Diagnostics AB Business Description

Traded in Other Exchanges
Address
Gasverksgatan 3A, Lund, SWE, 222 29
Prolight Diagnostics AB along with its subsidiaries, develops Point-of-Care (POC) systems, which are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. Its product portfolio includes Psyros, a digital POC technology, and Microflex.

Prolight Diagnostics AB Headlines

No Headlines